HK1220385A1 - 用於增加瘦素生成的比馬前列素 - Google Patents

用於增加瘦素生成的比馬前列素

Info

Publication number
HK1220385A1
HK1220385A1 HK16108521.3A HK16108521A HK1220385A1 HK 1220385 A1 HK1220385 A1 HK 1220385A1 HK 16108521 A HK16108521 A HK 16108521A HK 1220385 A1 HK1220385 A1 HK 1220385A1
Authority
HK
Hong Kong
Prior art keywords
bimatoprost
enhancement
leptin production
leptin
production
Prior art date
Application number
HK16108521.3A
Other languages
English (en)
Inventor
Neil J Poloso
Robert M Burk
Michael E Garst
David F Woodward
Timothy J Maziasz
Suzanne Kanaly
Grantley Charles
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of HK1220385A1 publication Critical patent/HK1220385A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16108521.3A 2013-03-15 2016-07-19 用於增加瘦素生成的比馬前列素 HK1220385A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361793132P 2013-03-15 2013-03-15
PCT/US2014/026110 WO2014143629A1 (en) 2013-03-15 2014-03-13 Bimatoprost for enhancement of leptin production

Publications (1)

Publication Number Publication Date
HK1220385A1 true HK1220385A1 (zh) 2017-05-05

Family

ID=50442712

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16108521.3A HK1220385A1 (zh) 2013-03-15 2016-07-19 用於增加瘦素生成的比馬前列素

Country Status (11)

Country Link
US (2) US20140275272A1 (zh)
EP (1) EP2968361A1 (zh)
JP (1) JP2016513647A (zh)
KR (1) KR20150129735A (zh)
CN (1) CN105338985A (zh)
AU (1) AU2014228307A1 (zh)
BR (1) BR112015021859A2 (zh)
CA (1) CA2901529A1 (zh)
HK (1) HK1220385A1 (zh)
RU (1) RU2015134772A (zh)
WO (1) WO2014143629A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9795615B2 (en) 2015-04-30 2017-10-24 Allergan, Inc. Methods for fat reduction

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DE69212850T2 (de) 1991-01-15 1997-03-06 Alcon Lab Inc Verwendung von Karrageenan in topischen ophthalmologischen Zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US7666912B2 (en) * 2006-03-23 2010-02-23 Massachusetts Eye And Ear Infirmary Compositions and methods for reducing body fat
WO2010100656A2 (en) * 2009-02-20 2010-09-10 Micro Labs Limited Storage stable prostaglandin product
WO2012099942A2 (en) * 2011-01-19 2012-07-26 Terakine Therapeutics, Inc. Methods and compositions for treating metabolic syndrome

Also Published As

Publication number Publication date
JP2016513647A (ja) 2016-05-16
KR20150129735A (ko) 2015-11-20
US20140275272A1 (en) 2014-09-18
AU2014228307A1 (en) 2015-09-10
WO2014143629A1 (en) 2014-09-18
EP2968361A1 (en) 2016-01-20
RU2015134772A (ru) 2017-04-21
CN105338985A (zh) 2016-02-17
RU2015134772A3 (zh) 2018-03-21
CA2901529A1 (en) 2014-09-18
US20160310505A1 (en) 2016-10-27
BR112015021859A2 (pt) 2017-07-18

Similar Documents

Publication Publication Date Title
GB201401248D0 (en) Method of manufacture
SG11201510747RA (en) Method for increasing expression of rna-encoded proteins
SG11201506284RA (en) Method of producing microparticles
GB201421334D0 (en) Synthesis of aeizeolite
PL2845905T3 (pl) Wytwarzanie oligosacharydów
GB201507664D0 (en) Composition & methods of screening
EP2971207A4 (en) PRODUCTION OF ALUMINUM-SCANDIUM ALLOYS
HK1214240A1 (zh) 用於製備酰亞胺基二硫酰化合物的方法
EP3049079A4 (en) Solid forms of ceftolozane
EP2981374A4 (en) CASTING METHOD
GB201319531D0 (en) Composition & methods of screening
IL241290A0 (en) Subprevir polymorphs and methods for their production
GB201305231D0 (en) Method of Manufacture
GB201318700D0 (en) Manufacture of microneedles
GB2518928B (en) Method of depilation
HK1220385A1 (zh) 用於增加瘦素生成的比馬前列素
EP2786402B8 (en) Method of mechanosynthetic manufacture
HK1216419A1 (zh) 合成方法
HK1219274A1 (zh) 噠嗪酮化合物的製備方法
EP3043646A4 (en) Methods of making 2-halonicotinonitriles
EP2968557A4 (en) IMPROVING VACCINES
EP2947075A4 (en) PROCESS FOR THE SYNTHESIS OF THIADIAZOLYLAMIDE DERIVATIVE
GB201311291D0 (en) Method of manufacture
HK1210080A1 (zh) -羥基- -咪唑- -甲酰胺的硫酸鹽
GB201301262D0 (en) Method of manufacture